Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBITDA (2019 - 2025)

Burning Rock Biotech has reported EBITDA over the past 7 years, most recently at -$2.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 75.84% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached -$8.3 million, up 82.41%, while the annual FY2025 figure was -$8.5 million, 81.92% up from the prior year.
  • EBITDA for Q4 2025 was -$2.5 million at Burning Rock Biotech, up from -$2.6 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1.4 million in Q2 2025 and troughed at -$43.3 million in Q4 2021.
  • A 5-year average of -$20.8 million and a median of -$23.6 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 307.26% in 2021 and later soared 90.58% in 2025.
  • Year by year, EBITDA stood at -$43.3 million in 2021, then grew by 25.59% to -$32.2 million in 2022, then rose by 27.75% to -$23.3 million in 2023, then soared by 55.68% to -$10.3 million in 2024, then surged by 75.84% to -$2.5 million in 2025.
  • Business Quant data shows EBITDA for BNR at -$2.5 million in Q4 2025, -$2.6 million in Q3 2025, and -$1.4 million in Q2 2025.